ESTEVE CDMO commences $15.5m expansion of US facility
Lucy Batizovsky | March 6, 2026 | News story | Manufacturing and Production | ESTEVE, US, expansion
ESTEVE CDMO, a global Contract Development and Manufacturing Organization (CDMO) specialising in small molecule active pharmaceutical ingredients (APIs) and pharmaceutical intermediates, announced it had commenced a $15.5m investment in the Chicago site, acquired in July 2025.
The expansion of the Morton Grove, Illinois, facility will enhance production capabilities and associated space through reactor upgrades to add powder transfer systems, and the addition of jacket insulation and a single thermal fluid circuit to enhance thermal management, simplify validation under GMP conditions, and broaden the reactors’ operational temperature range.
After the upgrade, the reactors will be capable of operating between -15C and +140C (5F to 284F).
In addition, cleanroom and ancillary equipment upgrades will be made, including a computer-based supervisory control and data acquisition (SCADA) system. The SCADA system will monitor, control, and record manufacturing processes in real times.
Uninterruptible power supply (UPS) systems will also be installed to safeguard the efficient operation of quality control laboratories.
Andrea Oro, Managing Director US, said: “This investment reflects an important step in building a strong and sustainable US platform for ESTEVE CDMO.”
The facility was acquired to advance ESTEVE’s commitment to support pharmaceutical and biotech innovators to accelerate complex molecules to market. It provides ESTEVE, headquartered in Barcelona, with a physical presence in the US.
“It strengthens our ability to support customers earlier in development and accompany their programs through GMP manufacturing,” Oro added.
ESTEVE, part of ESTEVE Healthcare, specialises in small-molecule APIs and pharmaceutical intermediates, with over 60 years of experience in development and manufacturing and six sites across Spain, the United States, Mexico and China.
Related Content
Sharp invests $100m in US and EU manufacturing and packaging facilities
Sharp Services, a pharmaceutical packaging and sterile manufacturing specialist, has announced investments totalling $100m across …
ESTEVE expands into US market with acquisition of Regis Technologies
ESTEVE (Esteve Química), based in Barcelona, Spain, has acquired Regis Technologies, a contract development and …
Moderna doses first US patient in phase 1 trial of mRNA-4106 for solid tumours
The START Center for Cancer Research has dosed the first US participant in Moderna’s phase …
